Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 51.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,983 shares of the specialty pharmaceutical company’s stock after selling 40,653 shares during the period. Segall Bryant & Hamill LLC owned about 0.12% of Collegium Pharmaceutical worth $1,117,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. TD Private Client Wealth LLC raised its holdings in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares in the last quarter. Virtus Fund Advisers LLC acquired a new stake in Collegium Pharmaceutical during the third quarter valued at $72,000. KBC Group NV grew its position in Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after acquiring an additional 982 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock worth $196,000 after acquiring an additional 642 shares during the last quarter.

Collegium Pharmaceutical Stock Up 0.5 %

NASDAQ COLL opened at $29.71 on Friday. The business has a fifty day moving average price of $30.36 and a two-hundred day moving average price of $32.45. Collegium Pharmaceutical, Inc. has a fifty-two week low of $27.28 and a fifty-two week high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock has a market capitalization of $935.45 million, a PE ratio of 12.81 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares of the company’s stock, valued at $3,937,839.36. The trade was a 18.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Colleen Tupper sold 10,445 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the completion of the transaction, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently commented on COLL. Piper Sandler cut their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.